PE20090015A1 - Preparacion solida - Google Patents

Preparacion solida

Info

Publication number
PE20090015A1
PE20090015A1 PE2008000467A PE2008000467A PE20090015A1 PE 20090015 A1 PE20090015 A1 PE 20090015A1 PE 2008000467 A PE2008000467 A PE 2008000467A PE 2008000467 A PE2008000467 A PE 2008000467A PE 20090015 A1 PE20090015 A1 PE 20090015A1
Authority
PE
Peru
Prior art keywords
tablet
amount
solid preparation
weight regarding
methyl
Prior art date
Application number
PE2008000467A
Other languages
English (en)
Inventor
Yusuke Murukawa
Miyuki Hohokabe
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of PE20090015A1 publication Critical patent/PE20090015A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A UNA PREPARACION SOLIDA EN FORMA DE COMPRIMIDO QUE CONTIENE: A) UN GRANULO QUE COMPRENDE 2-[[6-[(3R)-3-AMINO-1-PIPERIDINIL]-3,4-DIHIDRO-3-METIL-2,4-DIOXO-1(2H)-PIRIMIDINIL]METIL]-4-FLUOROBENZONITRILO EN UNA CANTIDAD DE 25% A 40% EN PESO RESPECTO AL COMPRIMIDO Y CELULOSA MICROCRISTALINA EN UNA CANTIDAD DE 5% A 40% EN PESO RESPECTO AL COMPRIMIDO; Y B) EXCIPIENTES PARA FORMAR COMPRIMIDOS TALES COMO ESTEARATO DE MAGNESIO Y CELULOSA MICROCRISTALINA EN UNA CANTIDAD DE 2% A 20% EN PESO RESPECTO AL COMPRIMIDO. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION DEL COMPRIMIDO. DICHO COMPUESTO ES UN INHIBIDOR DE DIPEPTIDILPEPTIDASA (DPP-IV) UTIL EN EL TRATAMIENTO DE DIABETES TIPO 1 Y 2, OBESIDAD, HIPERLIPIDEMIA
PE2008000467A 2007-03-13 2008-03-12 Preparacion solida PE20090015A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2007064245 2007-03-13

Publications (1)

Publication Number Publication Date
PE20090015A1 true PE20090015A1 (es) 2009-01-30

Family

ID=39409986

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000467A PE20090015A1 (es) 2007-03-13 2008-03-12 Preparacion solida

Country Status (10)

Country Link
US (1) US7994183B2 (es)
EP (1) EP2120885A2 (es)
JP (1) JP5432720B2 (es)
AR (1) AR065698A1 (es)
CA (1) CA2680684A1 (es)
CL (1) CL2008000727A1 (es)
MX (1) MX2009009703A (es)
PE (1) PE20090015A1 (es)
TW (1) TW200900094A (es)
WO (1) WO2008114800A2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
PE20110297A1 (es) 2008-08-15 2011-05-26 Boehringer Ingelheim Int Inhibidores de dpp-4 para la cicatrizacion de heridas
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
TWI466672B (zh) 2009-01-29 2015-01-01 Boehringer Ingelheim Int 小兒科病人糖尿病之治療
NZ594044A (en) 2009-02-13 2014-08-29 Boehringer Ingelheim Int Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
MX2012001284A (es) * 2009-07-28 2012-03-26 Takeda Pharmaceutical Tableta.
CN102596191B (zh) 2009-10-02 2016-12-21 勃林格殷格翰国际有限公司 包含bi‑1356和二甲双胍的药物组合物
BR112012012641A2 (pt) 2009-11-27 2020-08-11 Boehringer Ingelheim International Gmbh TRATAMENTO DE PACIENTES DIABÉTICOS GENOTIPADOS COM INIBIDORES DE DPP-lVTAL COMO LINAGLIPTINA
US8648073B2 (en) 2009-12-30 2014-02-11 Fochon Pharma, Inc. Certain dipeptidyl peptidase inhibitors
WO2011113947A1 (en) 2010-03-18 2011-09-22 Boehringer Ingelheim International Gmbh Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
WO2011138421A1 (en) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
EP3366304B1 (en) 2010-06-24 2020-05-13 Boehringer Ingelheim International GmbH Diabetes therapy
JO3753B1 (ar) 2011-10-14 2021-01-31 Otsuka Pharma Co Ltd قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه
DK2851075T3 (da) * 2012-05-14 2022-01-31 Shionogi & Co Præparat, der indeholder 6,7-umættet -7-carbamoylmorphinanderivat
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2013179307A2 (en) * 2012-05-29 2013-12-05 Mylan Laboratories Limited Stabilized pharmaceutical compositions of saxagliptin
CN104519874B (zh) * 2012-06-05 2018-08-03 武田药品工业株式会社 固体制剂
EP2769712A1 (en) * 2013-02-21 2014-08-27 Siegfried International AG Pharmaceutical formulation comprising DPP-IV inhibitor agglomerates and DPP-IV inhibitor particles
CN106470704B (zh) * 2014-07-07 2020-07-31 雷科尔达蒂股份公司 药物剂型
CN104825413B (zh) * 2015-05-25 2019-12-20 浙江华海药业股份有限公司 一种含有琥珀酸曲格列汀的口服片剂及其制备方法
EP3310357A1 (en) * 2015-06-17 2018-04-25 H e x a l Aktiengesellschaft Alogliptin formulation
CN105596341B (zh) * 2016-03-14 2018-08-10 石家庄四药有限公司 一种琥珀酸曲格列汀固体制剂及制备方法
US20230365823A1 (en) 2021-04-01 2023-11-16 Sun Chemical Corporation Aqueous inkjet compositions comprising hydroxy-functional polyurethane dispersions

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5009897A (en) * 1988-06-24 1991-04-23 Abbott Laboratories Pharmaceutical granules and tablets made therefrom
JP2514078B2 (ja) * 1988-08-22 1996-07-10 エスエス製薬株式会社 圧縮成型製剤
CA1338596C (en) * 1988-09-27 1996-09-17 Hiroyoshi Koyama Granules having core and their production
JP3004758B2 (ja) * 1991-04-17 2000-01-31 旭化成工業株式会社 結合性、崩壊性に優れる加工澱粉
MXPA05006513A (es) * 2002-12-16 2005-09-08 Kissei Pharmaceutical Farmaco solido para uso oral.
US20080038341A1 (en) 2004-01-20 2008-02-14 James Kowalski Direct Compression Formulation And Process
EP1713780B1 (en) * 2004-02-05 2012-01-18 Probiodrug AG Novel inhibitors of glutaminyl cyclase
CN102134229B (zh) * 2004-03-15 2020-08-04 武田药品工业株式会社 二肽基肽酶抑制剂
PL1942898T5 (pl) 2005-09-14 2014-10-31 Takeda Pharmaceuticals Co Inhibitory peptydazy dipeptydylowej do leczenia cukrzycy
GEP20125701B (en) * 2006-09-13 2012-12-10 Takeda Pharmaceuticals Co Application of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethyl]-4-fluoro-benzonitrile
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
TW200836774A (en) 2007-02-01 2008-09-16 Takeda Pharmaceutical Solid preparation
US8093236B2 (en) * 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
CL2008002424A1 (es) * 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende un compuesto derivado de pirazol-o-glucosido; y uso de la composicion farmaceutica para el tratamiento de la diabetes mellitus, tolerancia anormal a la glucosa e hiperglucemia, trastornos metabolicos, entre otras.

Also Published As

Publication number Publication date
CA2680684A1 (en) 2008-09-25
WO2008114800A2 (en) 2008-09-25
WO2008114800A8 (en) 2009-04-09
TW200900094A (en) 2009-01-01
AR065698A1 (es) 2009-06-24
MX2009009703A (es) 2010-03-03
US7994183B2 (en) 2011-08-09
CL2008000727A1 (es) 2008-10-17
WO2008114800A3 (en) 2008-12-24
JP2010521416A (ja) 2010-06-24
EP2120885A2 (en) 2009-11-25
JP5432720B2 (ja) 2014-03-05
US20100105710A1 (en) 2010-04-29

Similar Documents

Publication Publication Date Title
PE20090015A1 (es) Preparacion solida
PE20081734A1 (es) Comprimido que comprende 2-[[6-[(3r)-3-amino-1-piperidinil]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)-pirimidinil]metil]-benzonitrilo y celulosa microcristalina
PE20141072A1 (es) Composiciones farmaceuticas de accion doble basadas en el bloqueo de los receptores de angiotensina y la inhibicion de la endopeptidasa neutral
IL243574B (en) A pharmaceutical preparation for use in the treatment of a disease treatable by blocking purine receptors
MX2009002274A (es) Compuestos de enlace fxr heterociclicos.
IN2012DN00790A (es)
CL2011002115A1 (es) Compuestos derivados de 5-fenil-1h-piridin-2-ona y 5-fenil-pirazin-2-ona, inhibidores de la tirosina-quinasa de bruton (btk); proceso de preparación de los compuestos, compuesto intermediario, composición farmacéutica y uso en el tratamiento de enfermedades inflamatorias y/o autoinmunes.
GEP20146072B (en) New compounds
EA201170198A1 (ru) Фармацевтические композиции, содержащие лиганды рецептора дофамина
MX2011008276A (es) Inhibidores de quinasa jun n-terminal.
CR9875A (es) Inhibidores de dipeptidilo peptidasa para tratar diabetes
EA201070164A1 (ru) Твердый препарат, включающий алоглиптин и гидрохлорид метформина
MX2011010332A (es) Compuestos de purina sustituidos con pirimidina como inhibidores de cinasa(s).
CR20120061A (es) Tableta
HN2011001446A (es) Compuesto utiles para inhibir chk1
MX2011012739A (es) Derivados fluorados de aminotriazol.
MX2011011733A (es) Inhiibidores de dihidroorotato deshidrogenasa como compuestos virostaticos.
MY152281A (en) 4-pyrimidinesulfamide derivative
PE20080376A1 (es) Formulaciones de comprimidos de liberacion inmediata de un antagonista del receptor de trombina derivado de fluorofenilpiridina
MA38126A1 (fr) 6-((s)-1-{1-[5-(2-hydroxy-éthoxy)-pyridin-2-yl]-1hpyrazol-3-yl}- éthyl)-3h1,3-benzothiazol-2-one comme antagoniste des récepteurs de l’ampa dépendants de tarp-gamma 8
PE20081801A1 (es) Formas solidas de un inhibidor de cinasa raf
UA101654C2 (uk) Матриксна фармацевтична композиція на основі гідросульфату (2-гідроксіетоксі)аміду 6-(4-бром-2-хлорфеніламіно)-7-фтор-3-метил-3н-бензоімідазол-5-карбонової кислоти
EA201170736A1 (ru) Синтез и новые солевые формы (r)-3-((e)-2-(пирролидин-3-ил)винил)-5-(тетрагидропиран-4-илокси) пиридина
MX2012001893A (es) Tableteado de eritritol e isomaltosa.
ATE546448T1 (de) Urotensin-ii-rezeptorantagonisten

Legal Events

Date Code Title Description
FD Application declared void or lapsed